Journal
JOURNAL OF IMMUNOTHERAPY
Volume 27, Issue 2, Pages 99-106Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00002371-200403000-00003
Keywords
endoglin; CTLs; single-chain diabodies
Categories
Ask authors/readers for more resources
We present a novel vascular tumor therapy approach based on lysing endothelial cells by cytotoxic T lymphocytes (CTLs). Retargeting of CTLs is achieved by a recombinant bispecific antibody molecule (bispecific single-chain diabody) directed against human endoglin (CD105, EDG) and the T-cell coreceptor CD3 (scDb EDGCD3). Bacterially expressed scDb EDGCD3 was able to bind to endoglin-expressing endothelial cells as well as CD3-expressing T lymphocytes. The single-chain diabody mediated killing of endothelial cells (HUVEC, HMEC) by activated cytotoxic T lymphocytes at picomolar concentrations, and cells not expressing endoglin were not affected. Because endoglin is up-regulated in the vasculature of many solid tumors, this antibody molecule should be capable of lysing tumor or endothelial cells and thus destroying the vascular bed of the tumor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available